Company intelligence / Profile preview
AngioGenex
New York, New York, United Statesangiogenex.com ↗
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
AngioGenex’s lead program, AGX-A, is a novel small molecule Id protein inhibitor under pre-clinical evaluation for oncology (cholangiocarcinoma) and ophthalmology (age-related macular degeneration); no clinical trial results publicly reported.
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
The Robert Benezra Lab at Sloan Kettering Institute
Beyond the preview
Go deeper on AngioGenex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioGenex.